Related Experiment Video
Updated: Jul 8, 2025
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Red Ginseng Is a Therapeutic Candidate for Chronic Doxorubicin-Induced Cardiomyopathy in Mice
Naoki Yoshikawa1, Naoto Hirata1, Yuichiro Kurone1
1Department of Pharmaceutical Health Care and Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
Abstract:
Doxorubicin-induced cardiomyopathy (DICM) is associated with a poor prognosis, and effective therapeutic drug candidates have yet to be identified. Furthermore, whether basic animal models reflect the clinical pathogenesis of DICM should be carefully examined. Although the exact mechanisms underlying the development of DICM are complex and remain unclear, oxidative stress is strongly implicated as a contributing factor. Therefore, we investigated the effects of ginseng (the root of Panax ginseng: Gin), an inexpensive and safe drug with antioxidant properties. We previously conducted a meta-analysis that yielded results suggesting its efficacy in humans. However, this study did not examine the efficacy of ginseng in detail. Therefore, this study investigated the efficacy of red ginseng (steamed and dried ginseng cultivated for over six years; RGin) in a mouse model of chronic DICM to elucidate its potential therapeutic benefits. RGin prevented the decrease in left ventricular ejection fraction associated with doxorubicin (DXR) administration and prolonged survival in DBA/2 mice. In addition, RGin reduced DXR-induced cardiomyocyte damage. These findings highlight its potential as a therapeutic option for the treatment of DICM.
Insights
Red ginseng (RGin) shows promise in treating doxorubicin-induced cardiomyopathy (DICM). This study found RGin protected against heart damage and improved survival in a mouse model, suggesting its therapeutic potential.
Area of Science:
- Cardiology
- Pharmacology
- Natural Products
Background:
- Doxorubicin-induced cardiomyopathy (DICM) has a poor prognosis with limited therapeutic options.
- Oxidative stress is a key factor in DICM pathogenesis, though mechanisms remain complex.
- Ginseng, a natural product with antioxidant properties, has shown potential efficacy.
Purpose of the Study:
- To investigate the therapeutic efficacy of red ginseng (RGin) in a mouse model of chronic DICM.
- To evaluate RGin's protective effects against doxorubicin (DXR)-induced cardiac damage and mortality.
Main Methods:
- DBA/2 mice were administered doxorubicin (DXR) to induce chronic cardiomyopathy.
- Mice were treated with red ginseng (RGin) to assess its protective effects.
- Left ventricular ejection fraction, survival rates, and cardiomyocyte damage were evaluated.
Main Results:
- RGin administration prevented the reduction in left ventricular ejection fraction caused by DXR.
- RGin significantly prolonged survival in DBA/2 mice treated with DXR.
- Histological analysis revealed that RGin reduced DXR-induced cardiomyocyte damage.
Conclusions:
- Red ginseng (RGin) demonstrates significant therapeutic potential for treating doxorubicin-induced cardiomyopathy (DICM).
- RGin's cardioprotective effects in a preclinical model warrant further investigation for clinical application.
